Alnylam Pharmaceuticals
(ALNY)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2004 | 12-2003 | 12-2002 | |
| Cash Flows From Operating Activities | |||
| Net Income | -32,654 | -25,033 | -4,136 |
| Depreciation Amortization | 2,444 | 838 | 36 |
| Accounts receivable | -859 | N/A | N/A |
| Accounts payable and accrued liabilities | -615 | 794 | 674 |
| Other Working Capital | 6,485 | 2,906 | 2,650 |
| Other Operating Activity | 5,629 | 7,667 | -502 |
| Operating Cash Flow | $-19,570 | $-12,828 | $-1,278 |
| Cash Flows From Investing Activities | |||
| Change In Deposits | -25,774 | N/A | N/A |
| PPE Investments | -8,821 | -3,119 | -562 |
| Net Acquisitions | N/A | -121 | N/A |
| Other Investing Activity | 373 | 0 | 0 |
| Investing Cash Flow | $-34,222 | $-3,240 | $-562 |
| Cash Flows From Financing Activities | |||
| Debt Issued | 7,201 | 2,098 | N/A |
| Debt Repayment | -1,859 | -3,203 | N/A |
| Common Stock Issued | 35,308 | 21 | 9 |
| Other Financing Activity | 9,954 | 24,792 | 17,308 |
| Financing Cash Flow | $50,604 | $23,708 | $17,317 |
| Exchange Rate Effect | 267 | 76 | N/A |
| Beginning Cash Position | 23,193 | 15,477 | N/A |
| End Cash Position | 20,272 | 23,193 | 15,477 |
| Net Cash Flow | $-2,921 | $7,716 | $15,477 |
| Free Cash Flow | |||
| Operating Cash Flow | -19,570 | -12,828 | -1,278 |
| Capital Expenditure | -9,006 | -3,119 | -562 |
| Free Cash Flow | -28,576 | -15,947 | -1,840 |